HRP20110666T1 - Uporaba 4-ciklopropilmetoksi-n-(3,5-diklor-1-oksidopiridin-4-il)-5-(metoksi)piridin-2-karboksamida u liječenju motoričkih poremećaja povezanih s parkinsonovom bolesti - Google Patents

Uporaba 4-ciklopropilmetoksi-n-(3,5-diklor-1-oksidopiridin-4-il)-5-(metoksi)piridin-2-karboksamida u liječenju motoričkih poremećaja povezanih s parkinsonovom bolesti Download PDF

Info

Publication number
HRP20110666T1
HRP20110666T1 HR20110666T HRP20110666T HRP20110666T1 HR P20110666 T1 HRP20110666 T1 HR P20110666T1 HR 20110666 T HR20110666 T HR 20110666T HR P20110666 T HRP20110666 T HR P20110666T HR P20110666 T1 HRP20110666 T1 HR P20110666T1
Authority
HR
Croatia
Prior art keywords
oxidopyridin
carboxamide
use according
disorders
cyclopropylmethoxy
Prior art date
Application number
HR20110666T
Other languages
English (en)
Croatian (hr)
Inventor
Delay-Goyet Philippe
Delgorge Claire
Menet Christine
Poughon Gilles
Ravinet-Trillou Christine
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20110666T1 publication Critical patent/HRP20110666T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
HR20110666T 2007-04-19 2008-04-16 Uporaba 4-ciklopropilmetoksi-n-(3,5-diklor-1-oksidopiridin-4-il)-5-(metoksi)piridin-2-karboksamida u liječenju motoričkih poremećaja povezanih s parkinsonovom bolesti HRP20110666T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
PCT/FR2008/000534 WO2008145841A1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
HRP20110666T1 true HRP20110666T1 (hr) 2011-10-31

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110666T HRP20110666T1 (hr) 2007-04-19 2008-04-16 Uporaba 4-ciklopropilmetoksi-n-(3,5-diklor-1-oksidopiridin-4-il)-5-(metoksi)piridin-2-karboksamida u liječenju motoričkih poremećaja povezanih s parkinsonovom bolesti

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR101503942B1 (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201503765XA (en) * 2012-11-28 2015-06-29 Sanofi Sa METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物
WO2025080415A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE69430747T2 (de) * 1993-07-28 2003-03-06 Aventis Pharma Ltd., West Malling Verbindungen als pde iv und tnf inhibitoren
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
EP1244649B1 (en) * 1999-12-23 2005-03-02 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
CA2439691A1 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
US20060004056A1 (en) * 2002-07-02 2006-01-05 Bernard Cote Di-aryl-substituted-ethan pyridone pde4 inhibitors
JP4727571B2 (ja) * 2003-03-12 2011-07-20 セルジーン コーポレイション Ｎ−アルキル−ヒドロキサム酸−イソインドリル化合物およびその薬学的使用
CA2611562A1 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
CL2008001136A1 (es) 2009-01-16
TWI439269B (zh) 2014-06-01
HK1141725A1 (en) 2010-11-19
CA2684174A1 (fr) 2008-12-04
JP2010524906A (ja) 2010-07-22
CN101663035A (zh) 2010-03-03
AR066108A1 (es) 2009-07-22
EA200970970A1 (ru) 2010-02-26
PA8776801A1 (es) 2008-11-19
ES2367408T3 (es) 2011-11-03
JO2678B1 (en) 2013-03-03
UY31035A1 (es) 2008-11-28
IL201448A0 (en) 2010-05-31
PL2146714T3 (pl) 2011-10-31
BRPI0810444A2 (pt) 2016-05-31
TW200911247A (en) 2009-03-16
WO2008145841A1 (fr) 2008-12-04
JP5386478B2 (ja) 2014-01-15
PT2146714E (pt) 2011-09-02
MY148092A (en) 2013-02-28
KR20150004885A (ko) 2015-01-13
RS51869B (sr) 2012-02-29
US20100130554A1 (en) 2010-05-27
NZ580482A (en) 2011-10-28
SI2146714T1 (sl) 2011-10-28
ATE513548T1 (de) 2011-07-15
EP2146714B1 (fr) 2011-06-22
MA31367B1 (fr) 2010-05-03
CY1111840T1 (el) 2015-10-07
CN101663035B (zh) 2012-06-20
ME00935B (me) 2012-06-20
DK2146714T3 (da) 2011-10-10
FR2915100A1 (fr) 2008-10-24
EP2146714A1 (fr) 2010-01-27
ZA200907251B (en) 2011-04-28
KR20090130059A (ko) 2009-12-17
AU2008257322A1 (en) 2008-12-04
MX2009011284A (es) 2009-11-02
FR2915100B1 (fr) 2009-06-05
KR101503942B1 (ko) 2015-03-18
IL201448A (en) 2014-08-31
EA019194B1 (ru) 2014-01-30
CA2684174C (fr) 2014-02-25
AU2008257322B2 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2013049751A3 (en) Methods and oral orthotic systems for use in connection with sleep - disordered breathing
BRPI1014433A2 (pt) "derivado de um composto ou um sal farmaceuticamente aceitável, composição farmacêutica ou nutracêutica, e métodos para tratar uma condição, para reduzir o desenvolvimento à tolerância a medicamentos vasodilatadores, para estimular a função mitocondrial em células, para melhorar a estrutura ou a função muscular em um animal e os efeitos mitocondriais associados com exercício em um animal, para intensificar a capacidade de exercício em um animal, a saúde e a função muscular, e a recuperação de músculos de atividade vigorosa ou do dano associado com atividade vigorosa ou sustentada em um animal, e, usos de epicatequina ou um derivado de epicatequina, de nicorandil ou um derivado de nicorandil e suas combinações."
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
DK1696904T3 (da) Anvendelse af rotigotin til behandling eller forebyggelse af dopaminergt neurontab
EP3904502A3 (en) Compositions and methods
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
EP3251674A3 (en) Antiviral azasugar-containing nucleosides
JP2015057451A5 (enExample)
HRP20110666T1 (hr) Uporaba 4-ciklopropilmetoksi-n-(3,5-diklor-1-oksidopiridin-4-il)-5-(metoksi)piridin-2-karboksamida u liječenju motoričkih poremećaja povezanih s parkinsonovom bolesti
GEP20146080B (en) Chromone derivatives, method of their preparation and therapeutic applications
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2008149802A1 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
JP2017526695A5 (enExample)
HRP20230070T1 (hr) Tasimelteon za liječenje smith-magenis sindroma
JP2011515470A5 (enExample)
HRP20130205T1 (hr) Sastavi koji sadrže apoekvorin i postupci njihove uporabe
MX340564B (es) Isoformas de neurregulina solubles activas modificadas post-traduccionalmente.
EA201390181A1 (ru) Несущий корпус для лекарственного средства и способ его изготовления
WO2008042314A3 (en) Diagnosis and treatment of disorders of the eye
RU2007122391A (ru) S-миртазапин для лечения приливов